Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1Phase 1/2 1Phase 1 1

Status

Completed 5Active not recruiting 4Recruiting 3Terminated 1Approved for marketing 1

Sponsor Class

NIH 6INDUSTRY 4OTHER 1

Study Type

Interventional 4

Sponsor

Cancer Type

Genitourinary 4

Conditions

Urothelial Cancer 2Urinary Bladder Neoplasms 1Carcinoma, Transitional Cell 1Acrocephalosyndactylia 1

Interventions

pembrolizumab 184Carboplatin 132Paclitaxel 101Cisplatin 101Gemcitabine 86Pemetrexed 79durvalumab 75Nivolumab 66Docetaxel 56atezolizumab 52Bevacizumab 50Cyclophosphamide 49Dexamethasone 45Capecitabine 45Oxaliplatin 43130-nm albumin-bound paclitaxel 41Rituximab 40Fulvestrant 39Lenalidomide 38Fluorouracil 38Prednisone 32osimertinib 31olaparib 29Leucovorin 29venetoclax 28fludarabine 28Trastuzumab 27Doxorubicin 27Etoposide 25Cetuximab 25

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Active not recruiting × INDUSTRY × erdafitinib × Clear all
NCT02365597 2026-06-05

An Efficacy and Safety Study of Erdafitinib (JNJ-42756493) in Participants With Urothelial Cancer

Janssen Research & Development, LLC

Phase 2 Active not recruiting
239 enrolled 32 charts 1 FDA
Genitourinary

Urothelial Cancer

NCT05567185 2026-06-05

TAR-210

Janssen Pharmaceutical K.K.

Phase 1 Active not recruiting
5 enrolled
Genitourinary

Acrocephalosyndactylia, Urinary Bladder Neoplasms

NCT03390504 2026-05-11

THOR

Janssen Research & Development, LLC

Phase 3 Active not recruiting
629 enrolled 32 charts
Genitourinary

Urothelial Cancer

NCT03473743 2026-03-30

A Study of Erdafitinib in Participants With Metastatic or Locally Advanced Urothelial Cancer

Janssen Research & Development, LLC

Phase 1/2 Active not recruiting
125 enrolled 19 charts
Genitourinary

Carcinoma, Transitional Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡